Cardinal Health, Inc.

Please stand by. We're about to begin. Good day and welcome to the Cardinal Health Incorporated fourth quarter fiscal year 2020 earnings conference call. Today's conference is being recorded. At this time, I'll turn the conference over to Mr. Kevin Moran. Please go ahead, sir.

Good morning. This is Kevin Moran, Vice President of Investor Relations. Thank you for joining us today. We hope you and your loved ones are healthy and safe. During the call, We will discuss Cardinal Health's fourth quarter and fiscal 2020 results, along with guidance for fiscal year 2021. Joining me are Mike Kaufman, Chief Executive Officer, and Jason Holler, Chief Financial Officer. You can find today's press release and presentation on the IR section of our website or at ir.cardinalhealth.com. During the call, we will be making forward-looking statements. The matters addressed in the statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filing and the forward-looking statement slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during the discussion today, our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. for all relevant periods can be found in the schedules attached in our press release. During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so that we can try and give everyone an opportunity. With that, I will now turn the call over to Mike.

Thanks, Kevin, and good morning to everyone joining us. Before Jason and I discuss our results in Outlook, let me share a few reflections. In my nearly 30 years as part of the Cardinal Health family, I have seen this company and this industry expand with new products, services, and markets, evolve with technology, regulatory, and model changes, and adapt when faced with external challenges. In each of these moments, we have demonstrated grit and agility. Now more than ever, we will lean on that legacy to navigate current challenges and perform our critical role in healthcare. In fiscal 20, we delivered on our commitments and demonstrated these traits. We grew operating earnings, exceeded our EPS guidance range, surpassed our enterprise cost savings target, and strengthened our balance sheet, all while continuing to execute our long-term strategic priorities in a rapidly changing environment. We made strategic portfolio decisions, including divesting our remaining equity interest in NaviHealth, as well as investing and partnering in the evolving growth areas of specialty, at home, and services. We achieved these results as we adapted our operations to address the unique challenges presented by COVID-19. We successfully transitioned our office employees to a remote work model and we continuously maintained operations in all of our distribution facilities, nuclear pharmacies, and global manufacturing plants. Through all of this, we kept our primary focus, delivering critical products and services to our customers, and at the same time, prioritizing the safety of our employees. As I look toward the coming year, I recognize that the global and industry dynamics resulting from the pandemic will continue to challenge areas of our business. I am confident that our team will continue rising to these challenges as we drive our strategic priorities forward. I'll provide some comments later about how I see these priorities evolving in fiscal 21 and beyond. But first, I'll turn to Jason to discuss the fourth quarter, fiscal 20, and our outlook for fiscal 21.